AbbVie Inc (ABBV)

ABBV (NYSE:Drugs)
$60.29
pos +0.77
+1.29%
Today's Range: 59.34 - 60.41 | ABBV Avg Daily Volume: 14,319,300
Last Update: 10/24/14 - 4:02 PM EDT
Volume: 10,390,674
YTD Performance: 12.71%
Open: $59.56
Previous Close: $59.52
52 Week Range: $45.50 - $60.02
Oustanding Shares: 1,591,699,124
Market Cap: 90,567,680,156
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 4
Moderate Buy 1 0 0 0
Hold 2 2 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.56 1.57 1.57 1.86
Latest Dividend: 0.42
Latest Dividend Yield: 3.18%
Dividend Ex-Date: 10/10/14
Price Earnings Ratio: 20.69
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
20.69 12.30 27.71
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
9.25% 23.15% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 5.40 0.00 0.00
Net Income 53.70 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ABBV:
EBITDA 6.97B
Revenue 18.38B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.78 $0.87 $3.17 $4.07
Number of Analysts 4 3 8 8
High Estimate $0.79 $0.92 $3.23 $4.65
Low Estimate $0.77 $0.83 $3.10 $3.70
Prior Year $0.82 $0.82 $3.14 $3.17
Growth Rate (Year over Year) -5.18% 6.10% 0.84% 28.39%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishAbbvie estimates, target increased at BMO

Oct 22, 2014 | 7:21 AM EDT

ABBV estimates were raised through 2015, BMO Capital said. Expect the company to exceed consensus and Hep-C can drive future growth. Outperform rating and new $61 price target. 

By

Sham Gad

 | Oct 21, 2014 | 3:00 PM EDT

There is virtually no room for error in a crowded trade.

By

Jim Cramer

 | Oct 17, 2014 | 12:48 PM EDT

We now have an investable bottom on our hands.

By

Tim Melvin

 | Oct 16, 2014 | 12:00 PM EDT

It's unlikely that they will be hit by Europe or the Ebola scare. 

By

Jim Cramer

 | Oct 15, 2014 | 3:57 PM EDT

There will likely be more selling until the elusive bottom is reached.

By

Doug Kass

 | Oct 15, 2014 | 8:32 AM EDT
 Where it began.
By

Antonia Oprita

 | Oct 15, 2014 | 5:30 AM EDT

The two tech giants help women freeze their eggs.

By

Stephanie Link

 | Oct 9, 2014 | 3:28 PM EDT

We are buying the weakness, albeit slowly.

updateAbbVie upgraded at UBS

Jul 28, 2014 | 8:03 AM EDT

ABBV was upgraded to Buy from Neutral, UBS said. Reflective of accretive Shire deal. $67 price target. 

bullishAbbvie added to US 1 List at BofA/Merrill

Jul 23, 2014 | 7:41 AM EDT

ABBV was placed on the US 1 list, according to Bank of America/Merrill Lynch said. Estimates also increased, given higher expected Hepatitis C sales and synergies from the Shire deal. 

GS has cleared the important hurdle on the way up which increases the odds for an eventual...
A good quarterly report has sent shares of Calamos Asset Management (CLMS) sharply higher....
Electronics distributor Ingram Micro (IM) reported better than 16% growth in its Q3 sendin...
Market posting decent day considering Ebola getting headlines again. Believe investors ha...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.